Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Latest filing alerts

Every SEC filing alert our engine sent, newest first: 8-K material events, deals, capital raises, leadership changes, results and insider buying and selling.

4:59 PM ET 8-K
Regulatory Approval Beta Bionics, Inc. BBNX

Beta Bionics Regulatory Approval

Beta Bionics received FDA clearance for Mint, its next-generation patch pump featuring a reusable and disposable architecture and smartphone control. The company also submitted a 510(k) application for its 3D Intelligence insulin dosing algorithm, which is expected to power its future automated insulin delivery platforms.

“We believe that our next-generation AID platform, consisting of Mint 3D and iLet 3D, will represent a transformational advancement for people living with diabetes, subject to regulatory clearance by the FDA.”

Sean Saint, President & CEO of Beta Bionics
8:31 AM ET 8-K
Regulatory Approval Scholar Rock Holding Corp SRRK

Scholar Rock Holding Regulatory Approval

Scholar Rock announced that the FDA has approved ISEMBYLD (apitegromab-mstn) for the treatment of spinal muscular atrophy in adults and children 2 years of age and older. The filing also clarifies that the approval includes a post-marketing requirement for a pregnancy safety study and a request for alert reports regarding bone fractures.

9:30 AM ET 8-K
Regulatory Approval Biofrontera Inc. BFRI

Biofrontera Regulatory Approval

Biofrontera received FDA approval for its supplemental New Drug Application (sNDA) for Ameluz in combination with the BF-RhodoLED lamp series to treat superficial basal cell carcinoma. This marks the first and only photodynamic therapy approved in the U.S. for a skin cancer, significantly expanding the addressable market for the company's PDT platform.

“FDA approval of Ameluz for superficial basal cell carcinoma is a defining milestone for Biofrontera. Ameluz is now the first and only photodynamic therapy approved in the United States to treat a skin cancer, which sets our platform apart in medical dermatology and gives dermatologists an effective, non-surgical option for a very common tumor.”

Hermann Luebbert, Chief Executive Officer and Chairman of Biofrontera
8:01 AM ET 8-K
Regulatory Approval Scholar Rock Holding Corp SRRK

Scholar Rock Holding Regulatory Approval

Scholar Rock received FDA approval for ISEMBYLD (apitegromab-mstn) for the treatment of spinal muscular atrophy (SMA) in adults and children aged 2 and older. This marks the first and only muscle-targeted treatment approved for SMA, representing a significant therapeutic breakthrough for the company's myostatin biology platform.

Earnings call
Sep 14, 2026, 8:00 AM ET

“Today’s FDA approval of ISEMBYLD marks a defining moment for the SMA community as we now launch the world’s first-ever muscle targeted treatment for children and adults living with SMA in the U.S. After decades of failed industry-wide efforts to unlock the potential of myostatin inhibition, Scholar Rock has delivered a therapeutic breakthrough with ISEMBYLD.”

David L. Hallal, Chairman and Chief Executive Officer of Scholar Rock
7:12 AM ET 8-K
Regulatory Approval Armata Pharmaceuticals, Inc. ARMP

Armata Pharmaceuticals Regulatory Approval

Armata Pharmaceuticals received FDA Breakthrough Therapy designation for its AP-SA02 product candidate for the treatment of complicated S. aureus bacteremia. The designation is supported by Phase 2 data showing a 100% clinical response rate without relapse at 28 days, compared to 75% for the placebo group. This status is intended to expedite the development and review of the therapy, which could potentially become the first antibacterial treatment approved based on superiority to current standard-of-care.

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.